Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19

Selina Wolfsberg, Claudia Gregoriano and Philipp Schuetz

ABSTRACT
Procalcitonin (PCT) is useful for differentiating between viral and bacterial infections and for reducing the unnecessary use of antibiotics. As the rise of antimicrobial resistance reaches “alarming” levels according to the World Health Organization, the importance of using biomarkers, such as PCT to limit unnecessary antibiotic exposure has further increased. Randomized trials in patients with respiratory tract infections have shown that PCT has prognostic implications and its use, embedded in stewardship protocols, leads to reductions in the use of antibiotics in different clinical settings without compromising clinical outcomes. However, available data are heterogeneous and recent trials found no significant benefit. Still, from these trials, we have learned several key considerations for the optimal use of PCT, which depend on the clinical setting, severity of presentation, and pretest probability for bacterial infection. For patients with respiratory infections and sepsis, PCT can be used to determine whether to initiate antimicrobial therapy in low-risk settings and, together with clinical data, whether to discontinue antimicrobial therapy in certain high-risk settings. There is also increasing evidence regarding PCT-guided therapy in patients with coronavirus disease 2019 (COVID-19). This review provides an up-to-date overview of the use of PCT in different clinical settings and diseases, including a discussion about its potential to improve the care of patients with COVID-19.

Abbreviations: CAP: community-acquired pneumonia; COVID-19: coronavirus disease 2019; CRP: C-reactive protein; DIC: disseminated intravascular coagulation; ED: emergency department; ECOPD: exacerbated chronic obstructive pulmonary disease; HAP: hospital-acquired pneumonia; ICU: intensive care unit; LOS: length of stay; MR-proADM: mid-regional pro-adrenomedullin; PCT: procalcitonin; SOFA: sequential organ failure assessment; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; VAP: ventilator-associated pneumonia; WHO: World Health Organization

Introduction
Almost ten years after its initial description in humans [1], the possible diagnostic, prognostic, and therapeutic qualities of the biomarker procalcitonin (PCT) were first discussed by Assicot et al. who found a correlation between elevated PCT levels and bacterial infection, with higher levels in severe cases as well as decreasing levels of PCT under antibiotic therapy [2]. PCT is the 116-amino-acid precursor of calcitonin [1], which is synthesized in the C cells of the thyroid in healthy individuals [3], resulting in PCT levels <0.1 μg/L [4]. In cases of bacterial infection, PCT is produced ubiquitously by organs, such as the lung, liver, kidney, brain, pancreas, small intestine, and heart with values increasing up to 1000-fold, as has been shown in experiments with animals [3]. A few hours after stimulation through endotoxins, including interleukin-1 (IL-1) and interleukin-6 (IL-6) or tumor necrosis factor α (TNFα), PCT levels start to rise and reach their peak at around 12 to 24 h and can persist for several days [4–6]. Other conditions that may also lead to increased PCT levels are other systemic infections (e.g. fungal-, parasitic-, but not autoimmune-mediated inflammation) [5,7,8], trauma [9], major surgery [10], severe burns [11], liver cirrhosis [12], acute pancreatitis [13], or aspiration pneumonitis [14], and they are physiologically increased in neonates during their first days of life [15,16]. Elevated PCT levels have also been found in patients with renal dysfunction [5].

In contrast, the expression of CALC-I, the gene responsible for calcitonin synthesis, was shown to be suppressed in viral infections through the release of cytokines, such as interferon-γ, leading to lower levels...
of PCT [17]. Thus, PCT has the potential to differentiate between viral and bacterial infections and to improve decisions regarding antibiotic use—a process also known as PCT-guided antibiotic stewardship. To reinforce just how important a more prudent use of antibiotics and antimicrobial stewardship programs are, in 2014, the World Health Organization (WHO) described the rise of antimicrobial resistance as “alarming” and concluded that a time when even minor infections might be fatal again was “a very real possibility for the twenty-first century” [18]. Here, a biomarker-based approach might help to support evidence-based antibiotic use and at the same time reduce risks for side effects from antibiotics.

However, the optimal use of PCT-guided antibiotic therapy has been discussed for a long time [19,20]. Many reviews and meta-analyses concluded that PCT is a good indicator of bacterial infection [21–24] and that overall antibiotics exposure can be reduced safely [25–36]. Some also found improved clinical outcomes, including lower mortality, particularly for discontinuation strategies in critically ill patients [37–42]. In addition, PCT has been discussed as a marker for illness severity, for example, in septic patients [43]. However, several trials concluded that prognostic evaluation of patients should not be based on PCT alone [44,45]. Further controversy persists due to the heterogeneity of trial data [26,46–49] and more recent trials reporting no significant benefits of PCT [26,50,51]. These differing results may be due to different settings, populations, and diseases all needing a specific approach, which makes general statements difficult. This is also reflected in the different cutoff values proposed by an international expert consensus paper in 2019 [52]. Therein, antibiotic therapy was recommended based on clinical assessment and a PCT cutoff value of ≥0.25 μg/L for patients with mild to moderate illness and ≥0.5 μg/L for patients admitted to the intensive care unit (ICU) [52]. The consensus further recommended serial PCT measurements to reevaluate the need for antibiotics as well as to consider reduction of >80% of peak PCT values as a strong indicator for early discontinuation of antibiotics [52].

This review will discuss established PCT use in light of the most recent knowledge for different settings and different diseases. The PCT-based approach for the treatment and management of patients suffering from the novel coronavirus disease 2019 (COVID-19) will be particularly emphasized.

**Primary care and general practice**

Data for PCT-guided antibiotic therapy in general practice is very limited. A Cochrane overview of systematic reviews from 2017 found one review that investigated the use of PCT in a primary care setting, based on only two trials [53]. Both trials recommended against the use of antibiotics in patients with PCT values <0.25 μg/L and suggested reassessing patients without clinical improvement within 24–48 h [34]. The Cochrane review concluded that PCT guidance reduced antibiotic prescription in acute upper and lower respiratory infections without impairing patient outcomes, attesting the available evidence moderate quality [53]. However, similar results were also demonstrated for the use of C-reactive protein (CRP) testing, though CRP differentiates between viral and bacterial infections less accurately [53,54]. They further noted that the overall effect, that is, the reduction in an antibiotic prescription, was small but “likely to be clinically important” [53].

Acute rhinosinusitis, another condition often encountered by general practitioners, was the subject of a systematic review published in 2019 [55]. Based on two randomized controlled trials, the review concluded that PCT-guided therapy was able to significantly reduce antibiotic use without negatively affecting patient outcomes, for example, impaired activity or missed workdays [55]. However, the authors caution that data are very limited and, in this case, based on only 245 patients in total [55].

For lower respiratory tract infections, more evidence is expected to emerge soon, as an ongoing randomized trial compares PCT testing to lung ultrasonography and standard of care in patients with suspected pneumonia in a general practice setting [56].

**Emergency department (ED)**

A systematic review of prospective trials found that PCT-guided therapy in the emergency department (ED) was safe and effective [57]. However, most of these trials focused on adult patients with respiratory infections, thus limiting generalizability to other patient populations [57]. In addition, protocol non-adherence was identified as one of the main issues in these trials [57].

After the review was published, another trial looked at a broad population of emergency patients by studying PCT management in patients with fever (HiTEMP study) [50]. Compared to the control group, they found non-inferiority of PCT-guided therapy regarding safety but no reduction in the number of patients who received antibiotic treatment and overall low accuracy for the diagnosis of infections, specifically lower than CRP [50]. In contrast, most previously published studies have reported otherwise, and two Cochrane reviews from 2017 found significantly lower exposure to
antibiotics in patients admitted to the ED with lower respiratory infections [41,53]. The higher cutoff value for PCT ($\geq 0.5 \mu g/L$), the heterogeneous study population, and low protocol adherence (66%) in the HiTEMP study may explain these differing results [50]. However, another clinical trial included only patients with acute lower respiratory tract infection, used a lower cutoff value for PCT ($\geq 0.25 \mu g/L$), reported a higher protocol adherence (73%), and still failed to find a significant reduction in antibiotic exposure [51]. Due to these differing results, more research and reappraisal of the use of PCT in different subgroups are required to determine which ED population benefits the most from PCT-guided therapy.

**Medical ward**

For hospitalized patients, serial PCT measurements are superior to single measurements regarding the prognostic value and monitoring of therapeutic success [4,16,58–61]. Specifically, discontinuation of antibiotics based on a reduction of PCT to 80% of its peak value has been tested in different settings, including medical, pediatric, and intensive care patients [4,37,58–61]. Again, most trials focused on respiratory diseases. However, different diagnoses require specific approaches to PCT-guided therapy, some of which, including COVID-19, will be discussed in the following paragraphs.

**Community-acquired pneumonia**

Two meta-analyses based on largely the same trials between 2006 and 2011, most of which used a PCT cutoff of 0.25 $\mu g/L$, found initiation, duration, and total exposure of antibiotics to be significantly reduced in PCT-guided therapy for patients with community-acquired pneumonia (CAP) [40,41]. However, they also reported high levels of interaction, suggesting subgroup differences, and neither analysis found a significant reduction in mortality [40,41]. In addition, a systematic review found that PCT is better as a prognostic than as a diagnostic tool for CAP [64], and a recent meta-analysis reported that a PCT cutoff of 0.5 $\mu g/L$ yielded low sensitivity and medium specificity, concluding that the biomarker should not be used to decide whether to initiate or discontinue antibiotic treatment [65]. These conclusions are further supported by more recent trials that failed to find a reduction of antibiotic use [51,66], and one study reported PCT to be outperformed by CRP and IL-6 regarding diagnostic accuracy for pneumonia in patients presenting with dyspnea [67]. These differing results may be explained by several factors, including low adherence and lower exposure in the control group due to changes in clinical practice, such as the establishment of short-course therapy [68]. Furthermore, CRP has been shown to differentiate between bacterial and viral infections less accurately than PCT [54], and the long turn-around time of IL-6 limits its use in clinical practice. It remains to be seen whether future trials will confirm these results.

**Hospital-acquired and ventilator-associated pneumonia (HAP/VAP)**

Two different guidelines for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are currently in use, one by the Infectious Diseases Society of America and the American Thoracic Society [69] and the other by a group of European and Latin American societies [70]. They recommend against the routine use of PCT for decisions regarding the initiation of antibiotics in these populations [69] and as a predictor for the patient outcome or measurement for treatment success [69,70]. However, both acknowledge the usefulness of PCT as an additional tool to clinical assessment to discontinue antibiotics, although the quality of evidence is lacking and further studies are needed [69,70].

**Chronic obstructive pulmonary disease (COPD)**

Several trials have investigated the use of PCT in patients with exacerbated chronic obstructive pulmonary disease (ECOPD), most of which used a 0.25 $\mu g/L$ PCT cutoff. Two meta-analyses summarizing trials from 2007 to 2016 found initiation, duration, and total exposure of antibiotics were significantly reduced in PCT-guided therapy patients compared to control group patients, without negative effects on outcomes [40,41]. However, they also reported high levels of interaction for some of their data, suggesting subgroup differences and neither analysis found a significant reduction in mortality [40,41]. Another meta-analysis from 2017 with a slightly different selection of trials also found a significant reduction of antibiotic exposure without a significant effect on mortality, length of stay (LOS), or treatment failure [28]. The significantly lower use of antibiotics was further confirmed by a meta-analysis conducted in 2020, which included trials until 2018 [71]. However, the authors did not support the use of PCT-guided therapy for ECOPD as the effect on antibiotic duration disappeared when trials with a high risk
for bias were excluded [71]. Thus, despite the general agreement that PCT-guided therapy can reduce antibiotic use, the quality, bias, and heterogeneity of the available evidence are insufficient and further research is needed, particularly for determining optimal cutoff values or comparing PCT to CRP [26–28,72].

**Coronavirus disease 2019 (COVID-19)**

During the current pandemic, there has been much interest in using PCT for managing patients with COVID-19, caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and first described in China in 2019 [73,74]. Patients with COVID-19 often present with unspecific symptoms also common in other respiratory diseases, making differentiation from bacterial infection challenging. Thus, the value of biomarkers, such as PCT and their diagnostic, prognostic, and therapeutic qualities were reassessed in light of the current pandemic. An overview of recent trials can be found in Table 1.

Based on a Cochrane meta-analysis from November 2020, routine laboratory testing, including PCT, has low sensitivity ranging from 0 to 48% and specificity from 26 to 95% to diagnose COVID-19 [75]. However, the authors also noted that certainty for their estimates was low to very low [75]. More recently, an Italian study also concluded that PCT did not help to distinguish between COVID-19 and other respiratory or febrile illnesses in a small observational study [76].

On the other hand, numerous studies reported that PCT levels correlated significantly with the severity of disease, complications, and clinical outcome of COVID-19 [77–92]. While initial analyses assumed that high PCT was a sign for bacterial superinfection [22] and high antibiotic administration [93,94], the rate of bacterial coinfection in COVID-19 patients has been shown to be as low as 7% [95], with higher rates among patients admitted to the ICU [95–97]. These numbers are significantly lower compared to patients with influenza, where bacterial infections were more frequent and a relevant cause of mortality [95]. Furthermore, PCT levels were also lower than those of pneumonia patients [76,98]. Thus, it is not yet clear whether PCT can be used as a marker of bacterial coinfection for COVID-19 patients in the same way it has been used in other respiratory diseases.

There are also recent data suggesting that PCT (>0.5 μg/L) could be an important prognostic indicator for hyperinflammation and the cytokine storm typically seen in severe COVID-19 progression [99]. Identification of patients at risk for disease progression may help to initiate anti-inflammatory medication early, thus reducing viral load and avoiding hyperactivation of the immune system [99]. In addition, a small Turkish study found higher PCT levels in severe COVID-19 patients with disseminated intravascular coagulation (DIC) [100]. The therapeutic consequences of elevated PCT levels should thus not only focus on antibiotic administration but also other treatment requirements.

During the COVID-19 pandemic, antibiotic overuse has become an important issue because patients often present with high severity of illness and high inflammation, and diagnosing bacterial superinfection in such a situation is challenging. The pandemic thus reduced the success of already established antimicrobial stewardship programs, for example, in the United Kingdom with more physicians using antibiotics despite the absence of bacterial infection [101]. Thus, the implementation and expansion of these programs have become even more important. Most of the studies investigating the usefulness of PCT-guided therapy in COVID-19 patients found reduced antibiotic use with no negative impact on outcomes [102–105]. However, study designs were observational and heterogeneous with small sample sizes, making strong conclusions difficult to draw. Further research is needed to determine the role of PCT in antimicrobial stewardship programs targeting COVID-19 patients.

**Other types of infections and settings**

There are several other areas where PCT may be useful, including meningitis [106,107], urinary tract infections [108], chronic heart failure [109–111], and acute asthma exacerbation [112]. Overall, PCT has shown promising results, though the lack of high-quality data does not allow for decisive conclusions or recommendations yet. Similarly, studies in low-income countries, where availability and relative cost of PCT testing may differ, report encouraging results, but these findings are also based on little data [113,114].

Other research areas where more data is needed concerning PCT-guided therapy are in immunosuppressed patients and those with neutropenia, two populations that have been excluded in most trials. However, there are two ongoing trials studying patients treated with anti-IL-6 therapy and patients with chemotheraputduced febrile neutropenia, respectively, which will hopefully advance the field further (INTER-ACT, ClinicalTrials.gov identifier: NCT04281602c; CALIF, ClinicalTrials.gov identifier: NCT03182465).
Table 1. Overview of discussed COVID-19 studies, including population descriptions, outcomes, and conclusions.

| Reference | Place, time of data collection | Design | No. of patients | Severity | Cutoff | Outcome(s) | Conclusion |
|-----------|-------------------------------|--------|-----------------|----------|--------|------------|------------|
| Zhou et al. | China, Dec 2019–Feb 2020 | n.a. | 70 COVID-19, 70 CAP | All | n.a. | COVID-19 compared to CAP | PCT higher in COVID-19 |
| Vaughan et al. | United States, Mar–Jun 2020 | Retrospective | 1705 | All | >0.5 µg/L, <0.1 µg/L | Bacterial coinfection | Positive predictive value 9.3%, Negative predictive value 98.3% |
| Dolci et al. | Italy, Feb–Mar 2020 | Retrospective | 83 | All | (1) <0.25 µg/L, (2) >6.7 µg/L | Bacterial coinfection, mortality | (1) 92% negative predictive value, 93% sensitivity |
| Van Berkel et al. | Netherlands, n.a. | n.a. | 66 | Severe (ICU) | >1 µg/L, <0.25 µg/L | Bacterial coinfection | (2) 92% positive predictive value, 27% sensitivity |
| Vanhomwegen et al. | Belgium, Mar–Jun 2020 | Retrospective | 66 | Severe (ICU) | (1) >0.5 µg/L, (2) >2.5 µg/L | Bacterial coinfection (within 48 h after ICU admission), 30 days mortality | (1) 80% sensitivity, 48% specificity; (2) 65% sensitivity, 85% specificity |
| Antibiotic prescription, exposure | Peters et al. | United Kingdom, Apr 2020 | Retrospective | 118 | Low/moderate (no ICU) | <0.25 µg/L | AB prescribed or stopped within 48 h | AB never started or stopped within 48 h in 72% |
| | Pulia et al. | United States, Mar–May 2020 | Retrospective | 73 | All | >0.25 µg/L | AB prescription | Reduced AB prescription in high PCT group |
| | Williams et al. | United Kingdom, Mar–Apr 2020 | Retrospective | 368 | All | ≤0.25 µg/L | AB prescription, mortality, ICU admission | Reduced AB prescription (without increasing mortality); higher mortality and ICU admittance in high PCT group |
| | Heesom et al. | United Kingdom, Apr–May 2020 | Prospective | 52 | Severe (ICU) | >0.5 µg/L | AB duration, ICU LOS | AB duration and ICU LOS longer in high PCT group |
| Other outcomes | Garrido et al. | Spain, Mar–May 2020 | Retrospective | 56 | All | n.a. | ICU admission, mortality | PCT higher in patients admitted to ICU and non-survivors |
| | Asoglu et al. | Turkey, Apr–Jun 2020 | Retrospective | 71 | Severe (ICU) | n.a. | DIC | PCT higher in patients with DIC |
| | Krause et al. | United States, Mar–Apr 2020 | Mixed (retrospective and prospective) | 93 | Severe (invasive mechanical ventilation) | >0.1 µg/L | Intubation duration, 28 days mortality | Intubation duration longer in high PCT group, no difference in mortality |

AB: antibiotics; AUC: area under the curve; CAP: community-acquired pneumonia; COVID-19: coronavirus disease 2019; DIC: disseminated intravascular coagulation; ICU: intensive care unit; LOS: length of stay; n.a.: not available; PCT: procalcitonin.

Sorted by outcome and severity.
Intensive care unit (ICU)

For critically ill patients with suspected infection, PCT has little opportunity to change initial antibiotic management but is recommended to help individualize and shorten treatment duration during the course of disease [4]. Two recent trials from France and the Netherlands tested PCT in a critical care setting [37,115]. The latter investigated a general ICU population based on a prospective, multicenter design and found both reduced antibiotic use and lower mortality in the PCT-guided group [37]. The French researchers, on the other hand, conducted a non-inferiority trial investigating patients with ECOPD, finding not only similar antibiotic use in their groups but also significantly higher mortality among PCT-guided patients [115].

Nevertheless, several recent meta-analyses found PCT-guided therapy to reduce antibiotic use when used for early discontinuation [20,36,39,116]. The benefit for mortality, however, was not reported in all studies. They also noted that methodologies and data regarding the use of PCT were very heterogeneous and meta-analyses might thus misrepresent its utility [117], resulting in evidence of low certainty and with a high risk of bias [39]. Furthermore, the reported survival benefit “occurred primarily in studies with low protocol adherence and studies with algorithms combining PCT with other biomarkers” and did not persist when excluding industry-sponsored trials [39]. Similarly, others found reduced mortality but only in discontinuation of PCT-algorithms [20,116] and not in trials with high protocol adherence or patients with high sequential organ failure assessment (SOFA) scores [20], whereas one meta-analysis reported no reduction in mortality at all [36]. Thus, more research is needed to determine whether PCT helps reduce mortality in an intensive care setting.

Sepsis

Sepsis is a complex condition that requires intensive care and timely intervention. Regarding PCT-guided therapy, the international guidelines of the Surviving Sepsis Campaign issued a weak recommendation for using PCT as a supportive tool to shorten antimicrobial therapy in patients with suspected sepsis, based on what they called low-quality evidence [118]. More recently, two meta-analyses from 2018 found reduced antibiotic use in PCT groups of 1.2 and 1.5 days, respectively, but came to different conclusions regarding mortality [42,119]. While one did not find an effect on either mortality or LOS [119], the other reported significantly lower mortality across different types of infections (respiratory, urinary, abdominal, etc.) [42]. Similarly, two recent trials from Greece and South Korea found a reduction in antibiotic use of up to 5 days but only the larger Greek study found a reduction in mortality [62,120]. Despite the heterogeneity of the data, overall results suggest that PCT is a good and safe complementary tool to discontinue antibiotics in sepsis, thus reducing antibiotic exposure, while its possible positive effect on mortality requires further research [47,121].

Department of surgery

PCT has been shown to be elevated in surgery patients, including those with severe trauma [9,122], severe burns [11,122], major surgery [10], liver cirrhosis [12], acute pancreatitis [13], or aspiration pneumonitis [14]. Levels increased even more in case of complications, such as sepsis [122]. A recent guideline by the World Society of Emergency Surgery included PCT in their recommendations for the management of severe acute pancreatitis [13]. According to them, PCT should be used to 1) detect pancreatic infection, as it is the most sensitive laboratory test available, and 2) assess the risk of infected pancreatic necrosis, as PCT is a strong negative predictor of this outcome [13].

PCT has also been investigated as a potential diagnostic and prognostic marker for infections and outcomes after heart [123] and liver [124] transplantation, aortic [125,126], and other types of cardiac surgery [127], as well as a hip replacement [128]. For other types of infections, the use of PCT has not been thoroughly investigated and recommended. For example, a systematic review recently discussed the role of PCT in periprosthetic joint infections, recommending against the use of PCT as a diagnostic tool to rule out infection [129], and a retrospective study of patients with chronic osteomyelitis came to a similar conclusion [130].

In sum, the role of PCT in a surgical setting is complex and data are controversial, requiring further research to understand the importance and optimal use of PCT in this setting.

Department of pediatrics

In children, PCT values vary depending not only on the factors discussed above but also on ones that are unique to the pediatric setting, such as gestational age or birth weight [16]. Furthermore, a physiological increase of PCT occurs in the first days of life with different courses for the term and preterm neonates [15,131,132]. The mode of delivery, on the other hand,
influences PCT less than CRP, making PCT a more reliable marker for postnatal sepsis [16].

Two analyses found PCT to accurately diagnose neonatal sepsis but also noted pronounced statistical heterogeneity in the analyzed data without being able to issue a clinical recommendation based on the data available [49,133]. More recently, the multicenter, randomized controlled NeoPIns trial showed PCT-guided therapy to be superior to standard care regarding the reduction of antibiotic use [35]. A secondary analysis of the same data concluded that serial measurements were able to exclude early-onset sepsis with high probability [134].

Much like for adults, sepsis is one of the most researched conditions for the use of PCT-guided antibiotic therapy in children. Other potential diseases include bacterial infection [135], where a recent review reported reduced antibiotic exposure and length of ICU stay [136], as well as bronchiolitis [137] and meningitis [107], all of which showed promising results.

Limitations and drawbacks of PCT

In addition to the specific drawbacks already mentioned above, there are also more general limitations to consider regarding the use of PCT in guiding antibiotic therapy and the interpretation of trial results.

First, different cutoff values and strategies, such as initiation vs. discontinuation of antibiotics, are necessary for different settings and diseases and depend on their severity. Thus, PCT recommendations need to be individualized based on patient comorbidities, for example, renal dysfunction. Second, the benefits of PCT-guided therapy may depend on health staff education and implementation. Physicians who have had little previous experience with PCT might be reluctant to adjust treatment based on laboratory results, leading to low protocol adherence. Similarly, high adherence might indicate high levels of trust in a test that physicians are already familiar with and use routinely, thus explaining differences among trial results regarding adherence and clinical benefits [20,39]. In addition, the presence of antimicrobial stewardship programs may lower the potential effect of PCT-guided therapy as compared to settings where few other systems are established to reduce the unnecessary use of antibiotics [138]. Also, the assays used to determine PCT levels differ in sensitivity and their performance varies for different settings, infections, and cutoffs, increasing the heterogeneity of trial data [139]. Assay utilization requires not only technical knowledge of their characteristics but also careful consideration of the clinical setting [139]. Furthermore, the relatively high cost of diagnostics and required infrastructure limits the use of PCT, particularly in low-income countries [113]. The role of industry sponsorship has also been discussed critically as some data suggest that industry-sponsored trials had better results than those without [39]. Finally, there are other emerging markers, such as mid-regional proadrenomedullin (MR-proADM) or presepsin, which may further improve the diagnostic and prognostic assessment of patients.

Conclusion

There is an increasing need to improve diagnosis and prognosis in patients with different types of infection. The host-derived biomarker PCT has been investigated in a large number of studies from different populations and settings, with sometimes contradictory conclusions. These discrepant findings may be due to several factors, including different cutoff values and strategies (e.g. initiation vs. discontinuation of antibiotics), routine implementation of PCT-guided therapy, protocol adherence, the use of different assays, or the presence of antimicrobial stewardship programs. There is a need for further research on the optimal way to use PCT alone and in conjunction with other emerging markers and diagnostic tools to improve the management of patients with infections.

Disclosure statement

Philipp Schuetz received support (paid to his employer) and research funding from bioMérieux SA, Thermo Fisher Scientific, Roche, Siemens, and Abbott for attending meetings and fulfilling speaking engagements. All other authors report no declarations of interest.

References

[1] Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett. 1984;167(1):93–97.
[2] Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518.
[3] Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.
[4] Brechot N, Hekimian G, Chastre J, et al. Procalcitonin to guide antibiotic therapy in the ICU. Int J Antimicrob Agents. 2015;46(Suppl 1):S19–S24.
[5] Covington EW, Roberts MZ, Dong J. Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature. Pharmacotherapy. 2018;38(5):569–581.
[6] Cleland DA, Eranki AP. Procalcitonin. Treasure Island (FL): StatPearls; 2021.

[7] Karzai W, Oberhoffer M, Meier-Hellmann A, et al. Procalcitonin—a new indicator of the systemic response to severe infections. Infection. 1997;25(6):329–334.

[8] Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitides) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250–1256.

[9] Mimoz O, Benoist JF, Edouard AR, et al. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med. 1998;24(2):185–188.

[10] Meissner M, Tschaikowsky K, Hutzel A, et al. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;24(7):680–684.

[11] Carsin H, Assicoli M, Feger F, et al. Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury. Burns. 1997;23(3):218–224.

[12] Attar BM, Moore CM, George M, et al. Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. WJG. 2014;20(9):2374–2382.

[13] Leppaniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.

[14] El-Solh AA, Vora H, Knight PR III, et al. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. Crit Care Med. 2011;39:1251–1256.

[15] Turner D, Hammerman C, Rudensky B, et al. Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram. Arch Dis Child Fetal Neonatal Ed. 2006;91(4):F283–F286.

[16] Eschborn S, Weitkamp JH. Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis. J Perinatol. 2019;39(7):893–903.

[17] Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–5584.

[18] World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva (Switzerland): World Health Organization; 2014.

[19] Paudel R, Dogra P, Montgomery-Yates AA, et al. Procalcitonin: a promising tool or just another over-hyped test? Int J Med Sci. 2020;17(3):332–337.

[20] Peng F, Chang W, Xie JF, et al. Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: a meta-analysis. Int J Infect Dis. 2019;85:158–166.

[21] Taylor R, Jones A, Kelly S, et al. A review of the value of procalcitonin as a marker of infection. Cureus. 2017;9(4):e1148.

[22] An PJ, Zhu YZ, Yang LP. Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. Pharmacol Res. 2020;159:104946.

[23] So-Ngern A, Leelasupasi S, Chulavatnatol S, et al. Prognostic value of serum procalcitonin level for the diagnosis of bacterial infections in critically-ill patients. Infect Chemother. 2019;51(3):263–273.

[24] van Berkel M, Kox M, Frenzel T, et al. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times? Crit Care. 2020;24(1):600.

[25] Shafiq N, Gauvin V, Pandey AK, et al. A meta-analysis to assess usefulness of procalcitonin-guided antibiotic usage for decision making. Indian J Med Res. 2017;146:576–584.

[26] Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe. 2019;15(4):296–304.

[27] Lin C, Pang Q. Meta-analysis and systematic review of procalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J. 2018;12(1):10–15.

[28] Mathioudakis AG, Chatzimavridou-Grigoradiou V, Corlateanu A, et al. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017;26:160073.

[29] Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESMIC systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med. 2012;38(6):940–949.

[30] McDonagh MS, Peterson K, Winthrop K, et al. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res. 2018;46(8):3337–3357.

[31] Meier MA, Branche A, Neeseer OL, et al. Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. Clin Infect Dis. 2019;69(3):388–396.

[32] Oppert M. [Diagnosis of sepsis and guidance of antibiotic therapy]. Med Klin Intensivmed Notfmed. 2019;114(4):286–289.

[33] Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care. 2013;17(6):R291.

[34] Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(5):651–662.

[35] Stocker M, van Herk W, EI Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPins). Lancet. 2017;390(10097):871–881.

[36] Zhang T, Wang Y, Yang Q, et al. Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis. BMC Infect Dis. 2017;17(1):514.
[37] de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–827.

[38] Huang HB, Peng JM, Weng L, et al. Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis. Ann Intensive Care. 2017;7(1):114.

[39] Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-Guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis. Chest. 2019;155(6):1109–1118.

[40] Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level Meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.

[41] Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498.

[42] Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level Meta-analysis of randomized trials. Crit Care. 2018;22(1):191.

[43] Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017;15(1):15.

[44] Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. PLOS One. 2018;13(11):e0206527.

[45] Zhao Y, Li C, Jia Y. Evaluation of the mortality in emergency department sepsis score combined with procalcitonin in septic patients. Am J Emerg Med. 2013;31(7):1086–1091.

[46] Li H, Luo YF, Blackwell TS, et al. Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother. 2011;55(12):5900–5906.

[47] Nunnally ME, Patel A. Sepsis – what’s new in 2019? Curr Opin Anaesthesiol. 2019;32(2):163–168.

[48] Pugh R, Grant C, Cooke RP, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015;(8):CD007577.

[49] Vouloumanou EK, Plessa E, Karageorgopoulou DE, Mantadakis E, et al. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med. 2011;37(5):747–762.

[50] van der Does Y, Limper M, Jie KE, Schuit SCE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect. 2018;24(12):1282–1289.

[51] Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–249.

[52] Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308–1318.

[53] Tonkin-Crine SK, Tan PS, van Hecke O, et al. Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews. Cochrane Database Syst Rev. 2017;(9):CD012252.

[54] Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–217.

[55] Dilger AE, Peters AT, Wunderink RG, et al. Procalcitonin as a biomarker in rhinosinusitis: a systematic review. Am J Rhinol Allergy. 2019;33(2):103–112.

[56] Lhopitallier L, Kronenberg A, Meuwly JY, et al. Procalcitonin and lung ultrasonography point-of-care testing to decide on antibiotic prescription in patients with lower respiratory tract infection in primary care: protocol of a pragmatic cluster randomized trial. BMC Pulm Med. 2019;19(1):143.

[57] van der Does Y, Rood PP, Haagsma JA, et al. Procalcitonin-guided therapy for the initiation of antibiotics in the ED: a systematic review. Am J Emerg Med. 2016;34(7):1286–1293.

[58] Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: Results from the multicenter procalcitonin MOonitoring SEpsis (MOSES) study. Crit Care Med. 2017;45(5):781–789.

[59] Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. Clin Biochem Rev. 2017;38(2):59–68.

[60] Downes KJ, Fitzgerald JC, Weiss SL. Utility of procalcitonin as a biomarker for sepsis in children. J Clin Microbiol. 2020;58(7):e01851-19.

[61] Rhee C. Using procalcitonin to guide antibiotic therapy. Open Forum Infect Dis. 2017;4:ofw249.

[62] Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med. 2021;203(2):202–210.

[63] Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–1066.

[64] Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community-acquired pneumonia—a systematic review. Dan Med J. 2012;59(3):A4357.

[65] Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538–542.

[66] Montassier E, Javaudin F, Moustafa F, et al. Guideline-Based clinical assessment versus procalcitonin-guided antibiotic use in pneumonia: a
pragmatic randomized trial. Ann Emerg Med. 2019; 74(4):580–591.

[67] Wussler D, Kozhuharov N, Tavares Oliveira M, et al. Clinical utility of procalcitonin in the diagnosis of pneumonia. Clin Chem. 2019;65(12):1532–1542.

[68] Kaziuni K, Sotiriou A, Dimopoulos G. Duration of pneumonia therapy and the role of biomarkers. Curr Opin Infect Dis. 2017;30(2):221–225.

[69] Falini AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111.

[70] Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J. 2017;50:1700582.

[71] Chen K, Pleasants KA, Pleasants RA, et al. Procalcitonin for antibiotic prescription in chronic obstructive pulmonary disease exacerbations: systematic review, meta-analysis, and clinical perspective. Pulm Ther. 2020;6(2):201–214.

[72] Li Z, Yuan X, Yu L, et al. Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: an updated meta-analysis. Medicine. 2019;98(32):e16775.

[73] Hui DS, El, Madani TA, Ntoumi F, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.

[74] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401–402.

[75] Stegeman I, Ochodo EA, Guleid F, et al. Routine laboratory testing to determine if a patient has COVID-19. Cochrane Database Syst Rev. 2020;11:CD013787.

[76] Nazerian P, Gagliano M, Suardi LR, et al. Procalcitonin for the differential diagnosis of COVID-19 in the emergency department. Prospective monocentric study. Intern Emerg Med. 2021;16(6):1733–1735.

[77] Del Sole F, Farcomeni A, LoCocco L, et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13378.

[78] Eshazli RM, Toraah EA, Elgaml A, El-Mowafy M, et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a Meta-analysis of 6320 patients. PLOS One. 2020;15(8):e0238160.

[79] Figliozi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362.

[80] Huang I, Pranata R, Lim MA, et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.

[81] Izcovich A, Rugosa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLOS One. 2020;15(11):e0241955.

[82] Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine. 2020;99(47):e23315.

[83] Krause M, Douin DJ, Tran TT, et al. Association between procalcitonin levels and duration of mechanical ventilation in COVID-19 patients. PLOS One. 2020;15(9):e0239174.

[84] Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2020;26(3):107–108.

[85] Mudaris M, Fajar JK, Wulandari L, et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000Res. 2020;9:1107.

[86] Ponti G, Maccalfoni M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–399.

[87] Tjendra Y, Al Mana AF, Espeso AP, et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020;144(12):1465–1474.

[88] Yang L, Jin J, Luo W, et al. Risk factors for predicting mortality of COVID-19 patients: a systematic review and meta-analysis. PLOS One. 2020;15(9):e0243124.

[89] Zare ME, Wang Y, N, Kazestani A, et al. Procalcitonin has good accuracy for prognosis of critical condition and mortality in COVID-19: a diagnostic test accuracy systematic review and meta-analysis. Iran J Allergy Asthma Immunol. 2020;19:557–569.

[90] Zhang JJJ, Lee KS, Ang LW, et al. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis, and meta-regression analysis. Clin Infect Dis. 2020;71(16):2199–2206.

[91] Hariyanto TI, Japar KV, Kwenandar F, et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis. Am J Emerg Med. 2021;41:110–119.

[92] Garrido P, Cueto P, Rovira C, et al. Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2. Am J Emerg Med. 2021;46:525–531.

[93] Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459–2468.

[94] Vaughn VM, Gandhi T, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Infect Dis. 2020; 72(10):e533–e541.
Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (biomarkers in acute heart failure) trial. Eur J Heart Fail. 2012;14(3):278–286.

Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol. 2016;223:390–397.

Ibrahim WH, Mushraq K, Raza T, et al. Effects of procalcitonin-guided treatment on antibiotic use and need for mechanical ventilation in patients with acute asthma exacerbation: meta-analysis of randomized controlled trials. Int J Infect Dis. 2017;65:75–80.

Thwaites CL, Lundeg G, Dondorp AM, et al. Infection management in patients with sepsis and septic shock in resource-limited settings. In: Dondorp AM, Dunser MW, Schultz MJ, editors. Sepsis management in resource-limited settings. Geneva (Switzerland): Cham; 2019. p. 163–184.

van Griensven J, Cnops L, De Wegheleire A, et al. Point-of-care biomarkers to guide antibiotic prescription for acute febrile illness in sub-Saharan Africa: promises and caveats. Open Forum Infect Dis. 2020; 7(8):ofaa260.

Daubin C, Valette X, Thioliere F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med. 2018;44(4):428–437.

Lam SW, Bauer SR, Fowler R, et al. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. Crit Care Med. 2018;46(5):684–690.

Lam SW, Bauer SR, Duggal A. Procalcitonin-based algorithms to initiate or stop antibiotic therapy in critically ill patients: is it time to rethink our strategy? Int J Antimicrob Agents. 2016;47(1):20–27.

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.

Claxton AJ, Thompson-Leduc P, Kirson NY, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta-analysis. Crit Care Med. 2018;46:691–698.

Jeon K, Suh JK, Jang EJ, et al. Procalcitonin-guided treatment on duration of antibiotic therapy and cost in septic patients (PRODA): a multi-center randomized controlled trial. J Korean Med Sci. 2019;34(14):e110.

Gregoriano C, Heilmann E, Molitor A, et al. Role of procalcitonin use in the management of sepsis. J Thorac Dis. 2020;12(Suppl 1):S55–S15.

Azzini AM, Dorizzi RM, Sette P, et al. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the evidence based laboratory medicine. Ann Transl Med. 2020;8(9):610.

Madershahian N, Wittwer T, Strauch J, et al. Kinetic of procalcitonin in the early postoperative course following heart transplantation. J Card Surg. 2008;23(5):468–473.
Kaido T, Ogawa K, Fujimoto Y, et al. Perioperative changes of procalcitonin levels in patients undergoing liver transplantation. Transpl Infect Dis. 2014;16(5):790–796.

Varetto G, Castagno C, Trucco A, et al. Serum procalcitonin as a valuable diagnostic tool in the early detection of infectious complications after open abdominal aortic repair. Ann Vasc Surg. 2016;34:111–118.

Liu H, Luo Z, Liu L, et al. Early kinetics of procalcitonin in predicting surgical outcomes in type A aortic dissection patients. Chin Med J. 2017;130(10):1175–1181.

Amin DN, Pruitt JC, Schuetz P. Influence of major cardiopulmonary surgery on serum levels of procalcitonin and other inflammatory markers. Anaesth Intensive Care. 2012;40(5):760–766.

Bouaicha S, Blatter S, Moor BK, et al. Early serum procalcitonin level after primary total hip replacement. Mediators Inflamm. 2013;2013:927636.

Yoon JR, Yang SH, Shin YS. Diagnostic accuracy of interleukin-6 and procalcitonin in patients with peri-prosthetic joint infection: a systematic review and meta-analysis. Int Orthop. 2018;42(6):1213–1226.

Jiang N, Ma YF, Jiang Y, et al. Clinical characteristics and treatment of extremity chronic osteomyelitis in Southern China: a retrospective analysis of 394 consecutive patients. Medicine. 2015;94(42):e1874.

Assumma M, Signore F, Pacifico L, et al. Serum procalcitonin concentrations in term delivering mothers and their healthy offspring: a longitudinal study. Clin Chem. 2000;46(10):1583–1587.

Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis. 1998;26(3):664–672.

Pontrelli G, De Crescenzo F, Buzzetti R, et al. Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis. BMC Infect Dis. 2017;17(1):302.

Stocker M, van Herk W, El Helou S, Dutta S, et al. C-reactive protein, procalcitonin, and white blood cell count to rule out neonatal early-onset sepsis within 36 hours: a secondary analysis of the neonatal procalcitonin intervention study. Clin Infect Dis. 2020;73(2):e383–e390.

Milcent K, Faesch S, Gras-Le Guen C, et al. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. JAMA Pediatr. 2016;170(1):62–69.

Bobillo-Perez S, Rodriguez-Fanjul J, Jordan Garcia I. Is procalcitonin useful in pediatric critical care patients? Biomark Insights. 2018;13:1177271918792244.

Alejandre C, Guitart C, Balaguer M, et al. Use of procalcitonin and C-reactive protein in the diagnosis of bacterial infection in infants with severe bronchiolitis. Eur J Pediatr. 2021;180(3):833–842.

Hamade B, Huang DT. Procalcitonin: where are we now? Crit Care Clin. 2020;36(1):23–40.

Schuetz P, Bretsch C, Bernasconi L, et al. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. Expert Rev Mol Diagn. 2017;17(6):593–601.